功能性高危表型独立于一线治疗预测多发性骨髓瘤不良生存:CIBMTR数据二次分析
该研究基于CIBMTR三项研究数据,分析一线自体造血干细胞移植后早期进展(<12、<18或<24个月)的多发性骨髓瘤患者,比较含来那度胺标准三联诱导(VRD/KRD)与其他方案对进展后总生存的影响。结果显示VRD/KRD与其他方案的总生存无显著差异,功能性高危表型独立于一线治疗预测不良生存,提示需考虑T细胞衔接器二线治疗。
要点
- 功能性高危多发性骨髓瘤定义为一线自体移植后12-24个月内进展。
- VRD/KRD与其他诱导方案相比,进展后总生存无显著差异。
- 功能性高危表型独立于一线治疗预测不良生存,需考虑T细胞衔接器二线治疗。
核心结论
- 功能性高危多发性骨髓瘤是不良预后因素,不因一线治疗类型而改变。
研究设计与样本
- 研究合并CIBMTR三项研究(MM18-02、MM19-01、MM20-03)数据。
- 纳入2008至2018年接受一线自体造血干细胞移植后进展<12、<18或<24个月的患者,分别构成FHR12(n=465)、FHR18(n=672)、FHR24(n=853)队列。
主要发现
- FHR12队列中,VRD/KRD组(n=238)进展后总生存为21个月,其他方案组(n=227)为17个月(HR=1.2,95%CI:0.6-1.06)。
- 多变量模型中,VRD/KRD与其他方案的总生存HR为0.94(95%CI:0.7-1.3,p=0.69)。
- 一线治疗类型与移植至首次复发时间对总生存的预测无显著交互作用,FHR18和FHR24结果类似。
临床怎么用
- 功能性高危多发性骨髓瘤患者预后差,无论一线是否使用VRD/KRD。
- 此类患者可考虑T细胞衔接器作为二线治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Functional high-risk (FHR) multiple myeloma (FHRMM) is often defined as progression within 12-24 months of front-line autologous hematopoietic stem cell transplantation (AHSCT). For patients with early progression after suboptimal front-line therapies, it is challenging to assign the disease progression to a true FHR phenotype versus less effective front-line therapy. In this study, we combined data from three Center for International Blood and Marrow Transplant Research studies (MM18-02, MM19-01 and MM20-03). We included patients who received front-line AHSCT between 2008 and 2018 and had progression <12 (FHR12, n = 465), <18 (FHR18, n = 672) or <24 months (FHR24, n = 853) after AHSCT. We classified induction therapy as standard lenalidomide-containing triplets (bortezomib, lenalidomide, dexamethasone [VRD]/carfilzomib, lenalidomide, dexamethasone [KRD]) versus other (bortezomib, thalidomide, dexamethasone [VTD]/bortezomib, cyclophosphamide, dexamethasone [VCD]/bortezomib, dexamethasone [VD]/lenalidomide, dexamethasone [RD]) and studied the impact of front-line therapy on post-FHR overall survival (OS). In the FHR12 cohort (follow-up 48 months), the OS after VRD/KRD (n = 238) was 21 versus 17 months with other regimens (n = 227, hazard ratio [HR] = 1.2, 95% confidence interval [CI]: 0.6-1.06). In a multivariable model, the HR for OS was 0.94 (95% CI: 0.7-1.3, p = 0.69) for VRD/KRD versus other regimens. There was no significant interaction between type of first-line (1L) therapy and time from 1L AHSCT to first relapse in predicting OS. Similar results were seen for FHR18 and FHR24. FHRMM remains a negative prognostic factor irrespective of front-line therapy and warrants consideration of T-cell engagers' second-line therapy.
引用
- Goel U, Dragomirescu C, Zanwar S, et al. Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data. Br J Haematol. 2026. PMID: 42023513. doi:10.1111/bjh.70490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。